Oncolytics Biotech Inc (ONCY NASDAQ) stock market data APIs
$0.9058
0.01(1.1%)
as of July 15, 2026
Try our APIs with
free plan!
Oncolytics Biotech Inc Financial Data Overview
Price chart is built with
Anychart
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal ("GI") tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Prev. Close
0.9058
Open
0.9125
High
0.9487
Low
0.8935
52 wk Range
0.77-1.51
Market Cap
108 M
Shares Outstanding
119 M
EPS
-0.11
Beta
1.095
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Oncolytics Biotech Inc data using free add-ons & libraries
Get Oncolytics Biotech Inc Fundamental Data
Oncolytics Biotech Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -32 918 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-14
- EPS/Forecast: -0.07
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Oncolytics Biotech Inc News
New
Oncolytics' New U.S Patent Extends Pelareorep Manufacturing Protection Into 2044
(RTTNews) - Oncolytics Biotech Inc. (ONCY) has secured a new U.S. Patent that extends protection over the commercial manufacturing process of its investigational immunotherapy Pelareorep, marking anot...
Sector Update: Healthcare Stocks Advance in Afternoon Trading
Healthcare stocks edged higher Tuesday afternoon, with the NYSE Healthcare Index and the State Stree PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer
Oncolytics Biotech, Inc. SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep,...
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies
Issued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tu...
Get Oncolytics Biotech Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
